XML 49 R42.htm IDEA: XBRL DOCUMENT v3.26.1

Licensing Activities and Business Development - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended									3 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2026	Sep. 30, 2025	Jun. 30, 2025	May 31, 2025	Jan. 31, 2025	Oct. 31, 2023	May 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Mar. 31, 2023	Jun. 30, 2026	Dec. 31, 2024	Dec. 29, 2022
License and Stock Purchase Agreement [Member] | AbbVie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non refundable upfront fee									$ 0.6
License Agreement [Member] | AbbVie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment											$ 0.0
Milestone payments					$ 3.0
License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued													482,313
Future milestone payment											0.0
Non-refundable upfront payment							$ 4.0	$ 0.5
License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment											0.0
Upfront payment										$ 10.0
License Agreement [Member] | OBB [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received												$ 0.2
Future milestone recievable											0.0
License Agreement [Member] | OBB [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future consideration recievable on clinical												7.0
Future consideration recievable on regulatory												35.0
Future consideration recievable on sales milestones												$ 160.0
Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone recievable											0.0
Contingent and sales-based milestone payments				$ 50.0
Upfront cash payment				0.0
Development and Regulatory Milestone First Indication [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							50.0
Development and Regulatory Milestone Second Indication [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							35.0
Development and Regulatory First Indication First Milestone [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			$ 10.0
Development and Regulatory First Indication First Milestone [Member] | License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						$ 5.0
Development and Regulatory First Indication Second Milestone [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment											$ 15.0
Development and Regulatory First Indication Second Milestone [Member] | License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments		$ 10.0
Development and Regulatory Second Indication First Milestone [Member] | License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	$ 5.0
Development and Regulatory [Member] | License Agreement [Member] | Mabwell [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										127.5
Development [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									18.0
Development [Member] | Merger Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				5.6
Commercialization [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									45.0
Sales-based [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									$ 87.5
Sales-based [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							$ 120.0
Sales-based [Member] | License Agreement [Member] | Mabwell [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										$ 275.0
Sales-based [Member] | Merger Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				$ 20.0

X

- Definition

Amount of upfront payment received.

+ References

No definition available.

+ Details

Name:	iron_AmountOfUpfrontPaymentReceived
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Business combination contingent consideration sales based milestone payments.

+ References

No definition available.

+ Details

Name:	iron_BusinessCombinationContingentConsiderationSalesBasedMilestonePayments
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Future consideration recievable on clinical.

+ References

No definition available.

+ Details

Name:	iron_FutureConsiderationRecievableOnClinical
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Future consideration recievable on regulatory.

+ References

No definition available.

+ Details

Name:	iron_FutureConsiderationRecievableOnRegulatory
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Future consideration recievable on sales milestones.

+ References

No definition available.

+ Details

Name:	iron_FutureConsiderationRecievableOnSalesMilestones
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Future milestone payment.

+ References

No definition available.

+ Details

Name:	iron_FutureMilestonePayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Future milestone recievable.

+ References

No definition available.

+ Details

Name:	iron_FutureMilestoneRecievable
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	iron_MilestonePayments
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Non refundable upfront fee.

+ References

No definition available.

+ Details

Name:	iron_NonRefundableUpfrontFee
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontCashPayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Upfront non-refundable payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontNonRefundablePayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontPayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_LicenseAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_AbbvieDeutschlandGmbhCoKgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_MabwellTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_OakBayBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_MergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryFirstIndicationFirstMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryFirstIndicationSecondMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatorySecondIndicationFirstMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_CommercializationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_Sales-BasedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: